FDA vs EMA - Comparison of marketing authorisations issued in 2023
Pharma Value has developed a Comparison of Marketing Authorisations Issued by the FDA and EMA in 2023. The aim of the analysis is to provide a
15 January 2024
Pharma Value has developed a Comparison of Marketing Authorisations Issued by the FDA and EMA in 2023. The aim of the analysis is to provide a
The analysis addresses differences in regional access times for drug reimbursement in Italy. Following the official publication for drug reimbursement in the Gazzetta Ufficiale, the
The poster addresses the evolution of the utilisation of the AIFA 5% Fund, established in 2003 for the acquisition of orphan drugs and the treatment
Pharma Value will participate in ISPOR Europe 2023, which will be held from 12 to 15 November 2023 in Copenhagen. Flying to Denmark will be Ginevra Mastroianni, Institutional and
On 31 October 2023, the 'stamped' text of the Budget Law 2024 arrived in Parliament for the final approval process. Pharma Value analysed
On 3 and 4 July, the 2nd GIRF Congress - ISPOR Roma for Future Group - was held in Milan, aimed at young people who
Le nuove norme del panorama legislativo impongono una elevata attenzione all’accesso dei farmaci nel prossimo futuro. Dal 1° gennaio 2025 diventerà operativo il nuovo regolamento
È stata ratificata lunedì, 24 maggio 2023, in Conferenza Stato-Regioni, l’approvazione del Piano Nazionale Malattie Rare 2023-2026, realizzato dopo 7 anni di lavori, con il
In 2020, AIFA introduced the new simplified P&R negotiation procedures: simplified price and reimbursement procedure for drug negotiations
The 5% Fund for rare diseases, which allows access to medicines that are not yet marketed in Italy and represent a hope of cure for
